Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for ProQR Therapeutics N.V. (PRQR : NSDQ)
 
 • Company Description   
ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company's lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands.

Number of Employees: 166

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.18 Daily Weekly Monthly
20 Day Moving Average: 344,044 shares
Shares Outstanding: 105.21 (millions)
Market Capitalization: $229.36 (millions)
Beta: 0.36
52 Week High: $4.62
52 Week Low: $1.07
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 14.14% 9.07%
12 Week 94.64% 66.25%
Year To Date -17.74% -22.95%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
ZERNIKEDREEF 9
-
LEIDEN,P7 2333 CK
NLD
ph: 31-88-166-7000
fax: -
ir@proqr.com http://www.proqr.com
 
 • General Corporate Information   
Officers
Daniel de Boer - Chief Executive Officer
Dinko Valerio - chairman
Jurriaan Dekkers - Chief Financial Officer
Andrew Morris - Vice President
Sheila Sponselee - Chief People & Operations Officer

Peer Information
ProQR Therapeutics N.V. (CORR.)
ProQR Therapeutics N.V. (RSPI)
ProQR Therapeutics N.V. (CGXP)
ProQR Therapeutics N.V. (BGEN)
ProQR Therapeutics N.V. (GTBP)
ProQR Therapeutics N.V. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: N71542109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
Share - Related Items
Shares Outstanding: 105.21
Most Recent Split Date: (:1)
Beta: 0.36
Market Capitalization: $229.36 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.37 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.76
Price/Cash Flow: -
Price / Sales: 11.14
EPS Growth
vs. Year Ago Period: -10.00%
vs. Previous Quarter: -10.00%
Sales Growth
vs. Year Ago Period: 3.21%
vs. Previous Quarter: 8.53%
ROE
06/30/25 - -
03/31/25 - -53.49
12/31/24 - -61.18
ROA
06/30/25 - -
03/31/25 - -22.07
12/31/24 - -21.43
Current Ratio
06/30/25 - -
03/31/25 - 4.10
12/31/24 - 3.95
Quick Ratio
06/30/25 - -
03/31/25 - 4.10
12/31/24 - 3.95
Operating Margin
06/30/25 - -
03/31/25 - -157.04
12/31/24 - -147.04
Net Margin
06/30/25 - -
03/31/25 - -157.04
12/31/24 - -147.04
Pre-Tax Margin
06/30/25 - -
03/31/25 - -158.13
12/31/24 - -147.90
Book Value
06/30/25 - -
03/31/25 - 0.79
12/31/24 - 0.91
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©